Altered expression of microRNA‑92b‑3p predicts survival outcomes of patients with prostate cancer and functions as an oncogene in tumor progression

Wang,Gang; Cheng,Bo; Jia,Renfeng; Tan,Bo; Liu,Wenlong

doi:10.3892/ol.2020.12265

Altered expression of microRNA‑92b‑3p predicts survival outcomes of patients with prostate cancer and functions as an oncogene in tumor progression

Authors:
- Gang Wang
- Bo Cheng
- Renfeng Jia
- Bo Tan
- Wenlong Liu
View Affiliations

Affiliations: Department of Urology, Shengli Oilfield Central Hospital, Dongying, Shandong 257034, P.R. China
Published online on: November 3, 2020 https://doi.org/10.3892/ol.2020.12265
Article Number: 4
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The global incidence of prostate cancer (PCa) has been increasing in recent years. Meanwhile, some studies have indicated the association between malignancies, such as lung and gastric cancer and PCa, and microRNAs (miRNAs). The present study was designed to assess the prognostic value of miR‑92b‑3p in patients with PCa and further investigate the biological function of miR‑92b‑3p. Real‑time quantitative polymerase chain reaction was used to estimate the expression of miR‑92b‑3p in PCa tissues and cell lines compared with normal tissues and cells. Kaplan‑Meier method was used to analyze the overall survival rate of patients with PCa. A Cox regression analysis was used to verify the prognostic value of miR‑92b‑3p. The biological function of miR‑92b‑3p was investigated using cell experiments. The findings of the present study revealed the upregulated expression of miR‑92b‑3p in PCa tissues and cells compared with normal tissues and cells. The overexpression of miR‑92b‑3p was significantly associated with the distant metastasis status and Tumor‑Node‑Metastasis stage of patients with PCa and predicted poor prognosis of PCa. In addition, the cell experiment results indicated that miR‑92b‑3p overexpression in PCa cells promoted cell proliferation, migration and invasion. The present study revealed that the overexpression of miR‑92b‑3p predicted poor prognosis in patients with PCa. Decreased expression of miR‑92b‑3p can suppress PCa cell proliferation, migration and invasion, which indicated that miR‑92b‑3p may function as an oncogene and serve as a novel therapeutic target for PCa.

View Figures

View References

1	Castillejos-Molina RA and Gabilondo-Navarro FB: Prostate cancer. Salud Publica Mex. 58:279–284. 2016. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Pu YS, Chiang HS, Lin CC, Huang CY, Huang KH and Chen J: Changing trends of prostate cancer in Asia. Aging Male. 7:120–132. 2004. View Article : Google Scholar : PubMed/NCBI
4	Kimura T and Egawa S: Epidemiology of prostate cancer in Asian countries. Int J Urol. 25:524–531. 2018. View Article : Google Scholar : PubMed/NCBI
5	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
6	Perdana NR, Mochtar CA, Umbas R and Hamid AR: The risk factors of prostate cancer and its prevention: A literature review. Acta Med Indones. 48:228–238. 2016.PubMed/NCBI
7	Redman JM, Gulley JL and Madan RA: Combining immunotherapies for the treatment of prostate cancer. Urol Oncol. 35:694–700. 2017. View Article : Google Scholar : PubMed/NCBI
8	Gasnier A and Parvizi N: Updates on the diagnosis and treatment of prostate cancer. Br J Radiol. 90:201701802017. View Article : Google Scholar : PubMed/NCBI
9	Powell Gray B, Kelly L, Ahrens DP, Barry AP, Kratschmer C, Levy M and Sullenger BA: Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer. Proc Natl Acad Sci USA. 115:4761–4766. 2018. View Article : Google Scholar : PubMed/NCBI
10	Rupaimoole R, Calin GA, Lopez-Berestein G and Sood AK: miRNA deregulation in cancer cells and the tumor microenvironment. Cancer Discov. 6:235–246. 2016. View Article : Google Scholar : PubMed/NCBI
11	Esquela-Kerscher A and Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI
12	Markou A, Zavridou M and Lianidou ES: miRNA-21 as a novel therapeutic target in lung cancer. Lung Cancer (Auckl). 7:19–27. 2016.PubMed/NCBI
13	Wu HM and Kim SG: miRNA-324, a potential therapeutic target for paracetamol-induced liver injury. Stem Cell Investig. 3:672016. View Article : Google Scholar : PubMed/NCBI
14	Chen JY, Xu LF, Hu HL, Wen YQ, Chen D and Liu WH: miRNA-215-5p alleviates the metastasis of prostate cancer by targeting PGK1. Eur Rev Med Pharmacol Sci. 24:639–646. 2020.PubMed/NCBI
15	Zhang X and Wu J: Prognostic role of microRNA-145 in prostate cancer: A systems review and meta-analysis. Prostate Int. 3:71–74. 2015. View Article : Google Scholar : PubMed/NCBI
16	Long M, Zhan M, Xu S, Yang R, Chen W, Zhang S, Shi Y, He Q, Mohan M, Liu Q and Wang J: miR-92b-3p acts as a tumor suppressor by targeting Gabra3 in pancreatic cancer. Mol Cancer. 16:1672017. View Article : Google Scholar : PubMed/NCBI
17	Ma H, Wang LY, Yang RH, Zhou Y, Zhou P and Kong L: Identification of reciprocal microRNA-mRNA pairs associated with metastatic potential disparities in human prostate cancer cells and signaling pathway analysis. J Cell Biochem. 120:17779–17790. 2019. View Article : Google Scholar : PubMed/NCBI
18	Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR and Humphrey PA; Grading Committee, : The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: Definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 40:244–252. 2016.PubMed/NCBI
19	Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, et al: Staging system for breast cancer: Revisions for the 6th edition of the AJCC cancer staging manual. Surg Clin North Am. 83:803–819. 2003. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Zhao Y, Song Y, Yao L, Song G and Teng C: Circulating microRNAs: Promising biomarkers involved in several cancers and other diseases. DNA Cell Biol. 36:77–94. 2017. View Article : Google Scholar : PubMed/NCBI
22	Steinberg BA and Fang JC: Long-term outcomes of acute heart failure: Where are we now? J Am Coll Cardiol. 70:2487–2489. 2017. View Article : Google Scholar : PubMed/NCBI
23	Zhao L, Yu H, Yi S, Peng X, Su P, Xiao Z, Liu R, Tang A, Li X, Liu F and Shen S: The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer. Oncotarget. 7:45370–45384. 2016. View Article : Google Scholar : PubMed/NCBI
24	Wang L, Li B, Zhang L, Li Q, He Z, Zhang X, Huang X, Xu Z, Xia Y, Zhang Q, et al: miR-664a-3p functions as an oncogene by targeting Hippo pathway in the development of gastric cancer. Cell Prolif. 52:e125672019. View Article : Google Scholar : PubMed/NCBI
25	Gong M, Chen C, Zhao H, Sun M and Song M: miR-506 suppresses cervical cancer cell proliferation both in vitro and in vivo. Neoplasma. 65:331–338. 2018. View Article : Google Scholar : PubMed/NCBI
26	Zhang Y, Zhang D, Lv J, Wang S and Zhang Q: miR-410-3p promotes prostate cancer progression via regulating PTEN/AKT/mTOR signaling pathway. Biochem Biophys Res Commun. 503:2459–2465. 2018. View Article : Google Scholar : PubMed/NCBI
27	Kachakova D, Mitkova A, Popov E, Popov I, Vlahova A, Dikov T, Christova S, Mitev V, Slavov C and Kaneva R: Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer. DNA Cell Biol. 34:189–200. 2015. View Article : Google Scholar : PubMed/NCBI
28	Li C, Huo B, Wang Y and Cheng C: Downregulation of microRNA-92b-3p suppresses proliferation, migration, and invasion of gastric cancer SGC-7901 cells by targeting Homeobox D10. J Cell Biochem. 120:17405–17412. 2019. View Article : Google Scholar : PubMed/NCBI
29	Gong L, Ren M, Lv Z, Yang Y and Wang Z: miR-92b-3p promotes colorectal carcinoma cell proliferation, invasion, and migration by inhibiting FBXW7 in vitro and in vivo. DNA Cell Biol. 37:501–511. 2018. View Article : Google Scholar : PubMed/NCBI
30	Arisan ED, Rencuzogullari O, Freitas IL, Radzali S, Keskin B, Kothari A, Warford A and Uysal-Onganer P: Upregulated Wnt-11 and miR-21 expression trigger epithelial mesenchymal transition in aggressive prostate cancer cells. Biology (Basel). 9:522020.
31	Krebs M, Solimando AG, Kalogirou C, Marquardt A, Frank T, Sokolakis I, Hatzichristodoulou G, Kneitz S, Bargou R, Kübler H, et al: miR-221-3p regulates VEGFR2 expression in high-risk prostate cancer and represents an escape mechanism from sunitinib in vitro. J Clin Med. 9:6702020. View Article : Google Scholar
32	Zheng C, Guo K, Chen B, Wen Y and Xu Y: miR-214-5p inhibits human prostate cancer proliferation and migration through regulating CRMP5. Cancer Biomark. 26:193–202. 2019. View Article : Google Scholar : PubMed/NCBI
33	Hidayat M, Mitsuishi Y, Takahashi F, Tajima K, Yae T, Miyahara K, Hayakawa D, Winardi W, Ihara H, Koinuma Y, et al: Role of FBXW7 in the quiescence of gefitinib-resistant lung cancer stem cells in EGFR-mutant non-small cell lung cancer. Bosn J Basic Med Sci. 19:355–367. 2019.PubMed/NCBI
34	Xiao G, Li Y, Wang M, Li X, Qin S, Sun X, Liang R, Zhang B, Du N, Xu C, et al: FBXW7 suppresses epithelial-mesenchymal transition and chemo-resistance of non-small-cell lung cancer cells by targeting snai1 for ubiquitin-dependent degradation. Cell Prolif. 51:e124732018. View Article : Google Scholar : PubMed/NCBI